finance.yahoo.com ·
protalix biotherapeutics inc q1 2026 003442858
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedProtalix BioTherapeutics benefits from regulatory approval of Elfabrio's new dosing regimen, triggering a milestone payment and supporting revenue growth. The company is a biotech firm focused on enzyme replacement therapies; commercial impact is company-specific, not sector-wide. No scarcity or supply chain disruption identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Protalix reported Q1 2026 net income of $18.3 million, including a $25 million milestone payment from Chiesi.
- European Commission approved Elfabrio's new dosing regimen.
- Protalix targets 15-20% global market share for Elfabrio by 2031, with a $3.2 billion TAM.
- 2026 revenue guidance reaffirmed at $78-83 million; Elfabrio product revenues expected $33-35 million.
- Cash position $51 million, no debt.
Protalix's Elfabrio sees flat sentiment in the short term due to milestone payment and approval; impact muted within 24-48h.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort